PPARA and metabolic dysfunction-associated steatotic liver disease: Although this may be far-reaching from a clinical point of view, the interaction between PPAR-modulating pharmacological agents and EDCs in NAFLD patients with metabolic conditions presents an interesting aspect for future research, especially given the high worldwide prevalence of NAFLD.